5Tan M.Granisetron:new insights into its use for the treatment of chemother apyin-duced nausea and vomiting[J].expert opin pharmacother,2003,4(9):1563-1571
6Thongprasert S.Efficacy and tolerability of tropisetron in the preven-tion of cisplatin-induced nausea and vomiting in advanced non-small cell lung cancer[J].Acta Oncol,2000,39,221-224
2Farber L, Stratz TH, Bruckle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients[J]. Int J Clin Pharmacol Res, 2001,21(1):1-13
3Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists[J]. Scand J Rheumatol Suppl. 2000,113:37-45
4Simpson K, Spencer CM, Mc Clellan KJ, et al. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting[J]. Drugs, 2000,59 (6):1297-1315
5Chua DT, Sham JS, Kwong DL, et al. Comparative effcacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study[J]. Am J Clin Oncol. 2000,23 (2):185-191
6Yokoyama T. Pharmacological review of tropisetron[J]. Nippon Yakurigaku Zasshi. 1999,114 (4): 219-226
7RUBENSTEIN EB, GRALLA RJ, HAINSWORTH JD, et al. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy[J]. Cancer, 1997,79(4):1216-1224.
8BLEIBERG HH, SPIELMANN M, FALKSON G, et al. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study[J]. Clin Ther, 1995,17(2):238-251.
9ETTINGER DS, ELSENBERG PD, FITTS D, et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy[J]. Cancer, 1996,78(1):144-151.
10BURRIS H, HESKETH P, COHN J, et al. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy[J]. Cancer J Sci Am, 1996,2(1):85-90.
